Beyond weight — the bigger picture
Insulin resistance, cardiometabolic markers, sleep, and how GLP-1 therapy fits into long-term metabolic health.
Last reviewed
Topics in this cluster
- Insulin resistance
- HbA1c
- Cardiovascular outcomes
- Sleep & metabolism
- Setpoint
The bigger picture
The SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events with semaglutide in patients with overweight or obesity and pre-existing cardiovascular disease — a benefit signal that exists independently of the weight loss itself. The underlying mechanisms — improved insulin sensitivity, reduced visceral adiposity, lower systemic inflammation — are summarized in recent metabolic reviews and align with the Cleveland Clinic clinical overview of GLP-1 agonists.
Frequently asked questions
Do GLP-1 medications improve insulin sensitivity?+
Yes. GLP-1 receptor agonists improve both fasting and post-prandial glycemic control, and the resulting weight loss further improves peripheral insulin sensitivity — together producing meaningful HbA1c reductions even in non-diabetic users.
Are there metabolic benefits beyond weight loss?+
Trials have shown improvements in blood pressure, triglycerides, inflammatory markers, sleep apnea severity, and — in patients with established cardiovascular disease — major adverse cardiovascular events.
Knowledge graph · related nodes
How this page connects to the rest of the GLP-1 knowledge base. Each link spans a different cluster — follow the one that maps to your next question.